IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $46.40 Average PT from Brokerages

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) have been assigned an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $46.40.

Several equities analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Stephens reiterated an “overweight” rating and issued a $45.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Truist Financial set a $59.00 target price on shares of IDEAYA Biosciences in a research report on Monday, November 24th. JMP Securities initiated coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They issued a “market outperform” rating and a $41.00 price target for the company. Finally, Barclays initiated coverage on shares of IDEAYA Biosciences in a report on Thursday, September 4th. They set an “overweight” rating and a $40.00 price target on the stock.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new position in shares of IDEAYA Biosciences in the third quarter worth approximately $38,000. Abich Financial Wealth Management LLC bought a new position in IDEAYA Biosciences during the 3rd quarter worth approximately $58,000. PNC Financial Services Group Inc. lifted its position in shares of IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after purchasing an additional 1,546 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of IDEAYA Biosciences in the 2nd quarter worth approximately $61,000. Finally, Daiwa Securities Group Inc. boosted its stake in shares of IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after purchasing an additional 436 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $34.02 on Monday. The company’s 50 day moving average price is $31.61 and its two-hundred day moving average price is $26.44. The firm has a market capitalization of $2.98 billion, a P/E ratio of -18.29 and a beta of 0.04. IDEAYA Biosciences has a fifty-two week low of $13.45 and a fifty-two week high of $37.08.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.33 EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $1.45. The firm had revenue of $207.83 million during the quarter, compared to the consensus estimate of $59.98 million. On average, analysts expect that IDEAYA Biosciences will post -3.07 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.